DNAs encoding chimeric immunoglobulin light or heavy chains and

Details DNAs encoding chimeric immunoglobulin light or heavy chains and DNAs encoding chimeric immunoglobulin light or heavy chains and

1995-05-17

1999-03-02

Feisee, Lila

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

536 234, 536 235, 536 2353, 4353201, 435326, 435328, 435332, 435334, 435337, 435343, C07H 2104, C12N 1513, C12N 1563

Patent

active

058770062

ABSTRACT:
Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5114842 (1992-05-01), Plow et al.
patent: 5225181 (1993-07-01), Srivastava et al.
patent: 5275812 (1994-01-01), Gold et al.
patent: 5284751 (1994-02-01), Frelinger, III et al.
patent: 5336618 (1994-08-01), Coller
patent: 5387413 (1995-02-01), Coller
patent: 5440020 (1995-08-01), Coller
patent: 5470738 (1995-11-01), Frelinger, III et al.
Harris, W.J. and S. Emery, "Therapeutic Antibodies -- The Coming of Age", Tibtech, 11:42-44 (1993).
Harker, L., "Role of Platelets and Thrombosis in Mechanisms of Acute Occlusion and Restenosis After Angioplasty", Am. J. Cardiol., 60:20B-28B (1987).
Morrison, S.L. et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984).
McEver, R.P. and M.N. Martin, "A Monoclonal Antibody to a Membrane Glycoprotein Binds Only to Activated Platelets", J. Biol. Chem., 259(15):9799-9804 (1984).
Sun, L.K. et al., "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17 1A", Proc. Natl. Acad. Sci. USA, 84:214-218 (1987).
Coller, B. et al., "A Murine Monoclonal Antibody That Completely Blocks the Binding of Fibrinogen to Platelets Produces a Thrombasthenic-like State in Normal Platelets and Binds to Glycoproteins IIb and/or IIIa", J. Clin. Invest., 72:325-338 (1983).
Hanson, S.R. et al., "Effects of Monoclonal Antibodies against the Platelet Glycoprotein IIb/IIIa Complex on Thrombosis and Hemostasis in the Baboon", J. Clin. Invest., 81: 149-158 (1988).
Pidard, D. et al., "Interaction of AP-2, a Monoclonal Antibody Specific for the Human Platelet Glycoprotein IIb-IIIa Complex, with Intact Platelets", J. Biol. Chem., 258(20): 12,582-12,586 (1983).
Vermylen, J. et al.,"Role of Platelet Activation and Fibrin Formation in Thrombogenesis", J. Am. Coll. Cardiol., 8: 2B-9B (1986).
Sahagan, B.G. et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen", J. Immunol., 137(3): 1066-1074 (1986).
Coller, B.S. and L.E. Scudder, "Inhibition of Dog Platelet Function by In Vivo Infusion of F(ab').sub.2 Fragments of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor", Blood, 66(6): 1456-1459 (1985).
Coller, B.S. et al., "Antithrombotic Effect of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor in an Experimental Animal Model", Blood, 68(3):783-786 (1986).
Gold, H.K. et al., "Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation", Circulation, 77(3): 670-677 (1988).
Yasuda, T. et al., "Monoclonal Antibody against the Platelet Glycoprotein (GP) IIb/IIIa Receptor Prevents Coronary Artery Reocclusion after Reperfusion with Recombinant Tissue-type Plasminogen Activator in Dogs", J. Clin. Invest., 81:1284-1291 (1988).
Coller, B.S. et al., "Inhibition of Human Platelet Function in Vivo with a Monoclonal Antibody", Ann. Intern. Med., 109:635-638 (Oct. 1988).
Mickelson, J.K. et al., "Antiplatelet Monoclonal F(ab').sub.2 Antibody Directed Against the Platelet GPIIb/IIIa Receptor Complex Prevents Coronary Artery Thrombosis in the Canine Heart", J. Mol. Cell. Cardiol., 21: 393-405 (1989).
Coller, B.S. et al., "Abolition of In Vivo Platelet Thrombus Formation in Primates With Monoclonal Antibodies to the Platelet GPIIb/IIIa Receptor", Circulation, 80(6): 1766-1774 (1989).
Gold et al., "Pharmacodynamic Study of F(ab').sub.2 Fragments of Murine Monoclonal Antibody 7E3 Directed against Human Platelet Glycoprotein IIb/IIIa in Patients with Unstable Angina Pectoris", J. Clin. Invest., 86: 651-659 (Aug. 1990).
Jordan, R.E. et al., "Evaluation of the Potency and Immunogenicity of 7E3 F(ab').sub.2 and Fab Fragments in Monkeys", Circulation, 82 (Suppl. III): III-661, Abstract No. 2627 (1990).
Yasuda, T. et al., "Lysis of Plasminogen Activator-Resistant Platelet-Rich Coronary Artery Thrombus With Combined Bolus Injection of Recombinant Tissue-Type Plasminogen Activator and Antiplatelet GPIIb/IIIa Antibody", J. Am. Coll. Cardiol., 16: 1728-1735 (1990).
Bhattacharya, S., et al., "Chimerization of Monoclonal Antibody 7E3 Preserves the GPIIB/IIIA Receptor Blockade and Platelet Functional Inhibition of Murine 7E3", Clin. Res., 39(2):196A (1991).
Ellis et al., "Prospects for the Use of Antagonists to the Platelet Glycoprotein IIb/IIIa Receptor to Prevent Postangioplasty Restenosis and Thrombosis", J. Am. Coll. Cardiol., 17(6): 89B-95B (1991).
Coller et al., "Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents", Ann. N.Y. Acad. Sci., 614: 193-213 (1991).
Machin, S.J. et al., "Comparison of Clinical Efficacy of Murine and Chimeric 7E3 Monoclonal Antibodies on Platelet Function", Thromb. Haemostas., 65(6): 1180, Abstract No. 1746 (1991).
Bhattacharya, S. et al., "Chimeric (humanised) monoclonal antiplatelet antibody 7E3 produces prolonged dose-dependent inhibition of platelet function", Eur. Heart J., 12 (Abstr. Suppl.): 26, Abstract No. 238 (1991).
Tcheng, J.E. et al., "Chimeric Antiplatelet GPIIb/IIIa Receptor Antibody (C-7E3) in Elective PTCA: Safety and Platelet Function Inhibition", Circulation, 84(4) (Suppl.II): II-590, Abstract No. 2344 (1991).
Klieman, N.S. et al., "Profound Platelet Inactivation with 7E3 Shortly After Thrombolytic Therapy for Acute Myocardial Infarction: Preliminary Results of The TAMI 8 Trial", Circulation, 84(4) (Suppl II): II-522, Abstract No. 2076 (1991).
Bruggemann, M. et al., "The Immunogenicity of Chimeric Antibodies", J. Exp. Med., 170: 2153-2157 (1989).
LoBuglio, A.F. et al., "Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response", Proc. Natl. Acad. Sci. USA, 86: 4220-4224 (1989).
Khazaeli, M.B. et al., "Pharmacokinetics and Immune Response of .sup.131 I-Chimeric Mouse/Human B72.3 (Human .gamma.4) Monoclonal Antibody in Humans", Cancer Res., 51: 5461-5466 (1991).
Benjamin, R.J. et al., "Tolerance to Rat Monoclonal Antibodies, Implications for Serotherapy", J. Exp. Med., 163:1539-1552 (1986).
Herlyn, D. et al., "Specific Detection of Anti-Idiotypic Immune Responses in Cancer Patients Treated with Murine Monoclonal Antibody", J. Immunol. Methods, 85: 27-38 (1985).
Shawler, D.L. et al., "Human Immune Response to Multiple Injections of Murine Monoclonal IgG," J. Immunol. 135(2): 1530-1535 (1985).
Chatenoud, L. et al., "Restriction of the Human in vivo Immune Response Against the Mouse Monoclonal Antibody OKT3", J. Immunol. 137(3): 830-838 (1986).
Morrison, S.L. et al., "Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy", Cancer Investigation 6(2): 185-192 (1988).
Verrill, H. et al., "Clinical Trial of Wistar Institute 17-1A Monoclonal Antibody in Patients with Advanced Gastrointestinal Adenocarcinoma: A Preliminary Report," Hybridoma, 5 (Suppl. 1) S175-S183 (1986).
Jordan, R.E. et al. "A Dramatic Reduction of the Immunogenicity of the Anti-GPIIb/IIIa Monoclonal Antibody, 7E3 Fab, by Humanization of the Murine Constant Domains," Circulation, 83 Suppl. I): I-411, Abstract No. 1637 (1992).
Trang, J.M. et al., "Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1A) in Metastatic Adenocarcinoma Patients," Pharm. Res., 7(6): 587-592 (1990).
Meredith, R.F. et al., "Pharmacokinetics, Immune Response, and Biodistribution of Iodine-131-Labeled Chimeric Mouse/Human IgG1,k 17-1A Monoclonal Antibody," J. Nuc. Med., 32(6):116

Affiliated with

Also associated with

Rating

DNAs encoding chimeric immunoglobulin light or heavy chains and does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNAs encoding chimeric immunoglobulin light or heavy chains and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNAs encoding chimeric immunoglobulin light or heavy chains and will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-421862